RT Journal Article
T1 The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.
A1 Radin, Massimo
A1 Sciascia, Savino
A1 Erkan, Doruk
A1 Pengo, Vittorio
A1 Tektonidou, Maria G
A1 Ugarte, Amaia
A1 Meroni, Pierluigi
A1 Ji, Lanlan
A1 Belmont, H Michael
A1 Cohen, Hannah
A1 Ramires de Jesus, Guilherme
A1 Branch, D Ware
A1 Fortin, Paul R
A1 Andreoli, Laura
A1 Petri, Michelle
A1 Rodriguez, Esther
A1 Rodriguez-Pinto, Ignasi
A1 Knight, Jason S
A1 Atsumi, Tatsuya
A1 Willis, Rohan
A1 Gonzalez, Emilio
A1 Lopez-Pedrera, Rosario
A1 Rossi Gandara, Ana Paula
A1 Borges Gualhardo Vendramini, Margarete
A1 Banzato, Alessandra
A1 Sevim, Ecem
A1 Barbhaiya, Medha
A1 Efthymiou, Maria
A1 Mackie, Ian
A1 Bertolaccini, Maria Laura
A1 Andrade, Danieli
K1 Antiphospholipid antibodies
K1 Antiphospholipid syndrome
K1 Cardiovascular
K1 GAPSS
K1 Risk stratification
K1 Thrombosis
AB To assess whether patients with antiphospholipid syndrome (APS) and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) when compared to patients without recurrent thrombosis. In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous) compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS.
PB Elsevier
YR 2019
FD 2019-05-02
LK http://hdl.handle.net/10668/14055
UL http://hdl.handle.net/10668/14055
LA en
NO Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, et al.  The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin Arthritis Rheum. 2019 Dec;49(3):464-468
DS RISalud
RD Apr 19, 2025